The beneficial effects ofearly thrombolytic treatment in patients with acute myocardial infarction have been demonstrated in several large clinical trials.' Such treatment leads to patency of the infarct related coronary artery, limitation of infarct size, improved left ventricular function, and decreased mortality. These features are not equally reliable indicators of the efficacy of new thrombolytic agents, however. For example recanalisation of the coronary artery is not always associated with limitation of infarct size, improvement of left ventricular function, or decreased mortality. Accepted for publication 4 August 1987 who have most to gain from early thrombolytic treatment.5 6 The most sensitive indicator in the evaluation of thrombolytic treatment is infarct size as estimated by the cumulative release of enzymes from the myocardium.' 5 6 10 The usefulness of cumulative enzyme release as a marker of myocardial damage and the correlation of such estimates with necropsy data were shown in several studies."'4 But streptokinase profoundly influences the time course of enzyme release after acute myocardial infarction. '5 16 Such changes may reflect altered rates of enzyme elimination from plasma and this would invalidate comparison between streptokinase and other treatment. Accelerated washout of enzymes from the infarcted area could also influence the exposure of enzymes to denaturating conditions and could thus change the release of enzyme activity in plasma."7"9 Such effects would also affect the proportions in which labile and stable enzymes are released.
We studied the validity of enzyme tests after thrombolytic treatment. Multienzyme analysis of plasma samples was included in the protocol of a large trial on the effects of streptokinase after acute de Zwaan, Willems, Vermeer, Res, Verheugt, van der Laarse, Simoons, Lubsen, Hermens myocardial infarction and time-activity curves of several enzymes were determined. These data were analysed by a method that simultaneously estimates the elimination rates from plasma ofvarious enzymes and by calculation of cumulative release of these enzymes in the first few days after acute myocardial infarction.
Patients and methods
The study, carried out under the auspicies of the Netherlands Interuniversity Cardiology Institute, was part of a randomised controlled trial to compare early thrombolytic treatment with conventional treatment in patients with acute myocardial infarction. Full details on patient selection, treatment protocol, and clinical outcome in 269 treated patients and 264 controls have been published.'2 Briefly, the procedures were as follows.
Patients with acute myocardial infarction aged < 70 years were included in the trial if they were admitted to the coronary care unit within four hours of the onset of symptoms. The diagnosis of acute myocardial infarction was based on chest pain lasting > 20 minutes and electrocardiographic signs typical of myocardial infarction (that is ST segment elevation of at least 0-1 mV in a limb lead or 0-2 mV ST segment deviation in one of the precordial leads). Exclusion criteria included previous bypass surgery or treatment with streptokinase, recent bleeding or trauma, and inability to give informed consent. Eligible patients were registered by a telephone answering service which then allocated treatment. Only patients allocated to treatment with streptokinase were asked for informed consent 
where C(t) and E(t) are the activities still present in intravascular and extravascular spaces and the integral term encompasses eliminated activity. The extravascular pool E(t) is determined by the timedependent plasma activity and TER and ERR2:
Values of C(t) in equations (1) and (2) (1) and (2) for longer intervals.
Results Table 1 shows the distribution of patients with complete time-activity curves up to at least 48 hours after acute myocardial infarction. Data for some patients were incomplete because of death, early surgery or percutaneous transluminal coronary angioplasty, or refusal of informed consent after allocation to thrombolytic treatment. Figure 2 shows the plasma curves obtained from the three participating centres. The small number of patients from Leiden explains an increased variability in the right hand panel. Figure 2 shows that results from the three centres were similar and that it was acceptable to pool data. Early release of all enzymes was accelerated in the patients treated with streptokinase. This was further investigated by calculating the time th at which cumulative release of enzyme equalled half of the total quantity released (Q(th)= Q(48)/2). Accelerated release implies an earlier th and fig 3 shows that this was indeed found in patients treated with streptokinase. In all three groups treated with streptokinase th was significantly different from controls (p < 0 001, Mann-Whitney). It is interesting to find that early release was also increased in patients with unsuccessful thrombolysis. Apparently, the effect is not dependent on early coronary reperfusion.
Estimation of the fractional catabolic rate constants for creatine kinase, creatine kinase-MB, and aspartate aminotransferase is based on a fixed value of 0-015 per hour for c-hydroxybutyrate dehydrogen- Release of a-hydroxybutyrate dehydrogenase and creatine kinase-MB was faster in the treated group than in the controls and the reduction of enzyme release by streptokinase only became apparent after 36 hours (fig 5) . Figure 6 shows the relations between estimates of myocardial damage based on different enzymes. The strongest correlations were found between ahydroxybutyrate dehydrogenase and aspartate aminotransferase (r = 0 95 and r = 0-89 in streptokinase and control groups respectively) but creatine kinase and creatine kinase-MB also correlate well with a-hydroxybutyrate dehydrogenase (r = 073-0 89). This implies that estimates of myocardial injury can in principle be based on any of the enzymes studied. The choice of specific marker enzymes may be decided by considerations such as those of convenience, specificity, and accuracy.'" 
Discussion
Rapid release of aspartate transaminase, shown by early peak activities in plasma, was noted the first time that patients with acute myocardial infarction were treated with streptokinase." Since then the effect has been reported for creatine kinase6 -and lactate dehydrogenase" and after the administration, of urokinase.3 Early investigators ascribed this' phenomenon to accelerated wash-out of enzymes from the infarcted area caused by reperfusion. Later on the phenomenon of "reperfusion damage" became apparent: reperfusion of the 'myocardiumn after temporary ischaemia may result in a paradoxical exacerbation of cellular damage, associated with an immediate release of intracellular enzymes.35 '3 Accelerated wash-out probably contributes only marginally to this effect because it was also seen after reoxygenation of hypoxic monolayer heart cell cultures. 37 In these preparations typical wash-out effects can be excluded. So reperfusion seems to result in more rapid necrosis, probably of myocardial tissue that has already been irreversibly damaged.
Reperfusion obviously occurs after spontaneous coronary reopening or successful thrombolysis-that is in 85% of the patients treated with streptokinase in the original trial'-and this could explain the early release of enzymes in the treatment group (fig 2) . In fact, early peaking of creatine kinase activities has even been regarded as proof of successful reperfusion.">4 Figure 3 , however, shows that such early release also occurs in patients with persistence of coronary occlusion after treatment with streptokinase. One explanation for this observation is that reperfusion occurred in most of these patients in the first few hours after the end of coronary catheterisation. In five of these patients, however, persisting coronary occlusion was demonstrated before discharge from hospital and the median values of th for a-hydroxybutyrate dehydrogenase, creatine kinase, creatine kinase-MB, and aspartate aminotransferase were 12 9 h, 17-0, 14 In several clinical studies necropsy has shown highly significant correlations between infarct size and the release of creatine kinase (and creatine kinase-MB) in plasma."..." A similar result was obtained for the release of lactate dehydrogenase.'4 Moreover, the reduction in a-hydroxybutyrate dehydrogenase activity in the heart was equivalent to the increase in plasma activity" and the results shown in fig 4 confirm this relation for other enzymes as well. Figures 4 and 6 show that after acute myocardial infarction various enzymes are released in fixed proportions that are independent of thrombolytic treatment. This implies that several validation studies' ''4 are relevant to the enzymes we studied. It is important to note that the release in plasma in some of these studies was seriously underestimated because the apparent disappearance constant kd was used in the calculations instead of the fractional catabolic rate constant. 26 The two main conclusions of the present studythat (a) infarct size is independent of the enzyme chosen for estimation and (b) thrombolytic treatment does not 
